High-expression of ZBP-89 correlates with distal metastasis and poor prognosis of patients in clear cell renal cell carcinoma

Biochemical and Biophysical Research Communications

Volumn 426, Issue 4, 2012, Pages 636-642

  Cai, Mu Yan ^a   Luo, Rong Zhen ^a   Li, Yong Hong ^a   Dong, Pei ^a   Zhang, Zhi Ling ^a   Zhou, Fang Jian ^a   Chen, Jie Wei ^a   Yun, Jing Ping ^a   Zhang, Chris Zhi Yi ^a   Cao, Yun ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Clear cell renal cell carcinoma; Metastasis; Prognosis; ZBP 89

Indexed keywords

MESSENGER RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ZBP 89; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER TISSUE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DISTANT METASTASIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TISSUE SECTION; WESTERN BLOTTING;

ADULT; CARCINOMA, RENAL CELL; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867210076     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.08.146     Document Type: Article

References (25)

1. Rini B.I., Campbell S.C., Escudier B. Renal cell carcinoma. Lancet 2009, 373:1119-1132.
2. Janzen N.K., Kim H.L., Figlin R.A., Belldegrun A.S. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol. Clin. North. Am. 2003, 30:843-852.
3. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics. CA Cancer J. Clin. 2007, 57:43-66.
4. Motzer R.J., Russo P. Systemic therapy for renal cell carcinoma. J. Urol. 2000, 163:408-417.
5. Eichelberg C., Junker K., Ljungberg B., Moch H. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur. Urol. 2009, 55:851-863.
6. Hollingsworth J.M., Miller D.C., Daignault S., Hollenbeck B.K. Rising incidence of small renal masses: a need to reassess treatment effect. J. Nat. Cancer Inst. 2006, 98:1331-1334.
7. Zhang C.Z., Chen G.G., Lai P.B. Transcription factor ZBP-89 in cancer growth and apoptosis. Biochim. Biophys. Acta 1806, 2010:36-41.
8. Law G.L., Itoh H., Law D.J., Mize G.J., Merchant J.L., Morris D.R. Transcription factor ZBP-89 regulates the activity of the ornithine decarboxylase promoter. J. Biol. Chem. 1998, 273:19955-19964.
9. Wu Y., Zhang X., Salmon M., Zehner Z.E. The zinc finger repressor, ZBP-89, recruits histone deacetylase 1 to repress vimentin gene expression. Genes Cells 2007, 12:905-918.
10. Keates A.C., Keates S., Kwon J.H., Arseneau K.O., Law D.J., Bai L., Merchant J.L., Wang T.C., Kelly C.P. ZBP-89, Sp1, and nuclear factor-kappa B regulate epithelial neutrophil-activating peptide-78 gene expression in Caco-2 human colonic epithelial cells. J. Biol. Chem. 2001, 276:43713-43722.
11. Bai L., Merchant J.L. Transcription factor ZBP-89 cooperates with histone acetyltransferase p300 during butyrate activation of p21waf1 transcription in human cells. J. Biol. Chem. 2000, 275:30725-30733.
12. Vesely K., Jurajda M., Nenutil R., Vesela M. Expression of p53, cyclin D1 and EGFR correlates with histological grade of adult soft tissue sarcomas: a study on tissue microarrays. Neoplasma 2009, 56:239-244.
13. Moran A., Iniesta P., de Juan C., Garcia-Aranda C., Diaz-Lopez A., Benito M. Impairment of stromelysin-1 transcriptional activity by promoter mutations in high microsatellite instability colorectal tumors. Cancer Res. 2005, 65:3811-3814.
14. Frensing T., Kaltschmidt C., Schmitt-John T. Characterization of a neuregulin-1 gene promoter: positive regulation of type I isoforms by NF-kappaB. Biochim. Biophys. Acta 2008, 1779:139-144.
15. C.Z. Zhang, Y. Cao, J.P. Yun, G.G. Chen, P.B. Lai, Increased expression of ZBP-89 and its prognostic significance in hepatocellular carcinoma, Histopathology, 2012.
16. Bai L., Logsdon C., Merchant J.L. Regulation of epithelial cell growth by ZBP-89: potential relevance in pancreatic cancer. Int. J. Gastrointest. Cancer 2002, 31:79-88.
17. Chao C., Hellmich M.R. Gastrin, inflammation, and carcinogenesis. Curr. Opin. Endocrinol. Diabetes Obes. 2010, 17:33-39.
18. Galgano M.T., Hampton G.M., Frierson H.F. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod. Pathol. 2006, 19:847-853.
19. Taniuchi T., Mortensen E.R., Ferguson A., Greenson J., Merchant J.L. Overexpression of ZBP-89, a zinc finger DNA binding protein, in gastric cancer. Biochem. Biophys. Res. Commun. 1997, 233:154-160.
20. Holley-Guthrie E.A., Seaman W.T., Bhende P., Merchant J.L., Kenney S.C. The Epstein-Barr virus protein BMRF1 activates gastrin transcription. J. Virol. 2005, 79:745-755.
21. Fukayama M., Hino R., Uozaki H. Epstein-Barr virus and gastric carcinoma: virus-host interactions leading to carcinoma. Cancer Sci. 2008, 99:1726-1733.
22. Juncker-Jensen A., Romer J., Pennington C.J., Lund L.R., Almholt K. Spontaneous metastasis in matrix metalloproteinase 3-deficient mice. Mol. Carcinog. 2009, 48:618-625.
23. Tang C.H., Yamamoto A., Lin Y.T., Fong Y.C., Tan T.W. Involvement of matrix metalloproteinase-3 in CCL5/CCR5 pathway of chondrosarcomas metastasis. Biochem. Pharmacol. 2010, 79:209-217.
24. Bhuvarahamurthy V., Kristiansen G.O., Johannsen M., Loening S.A., Schnorr D., Jung K., Staack A. In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma. Oncol. Rep. 2006, 15:1379-1384.
25. Belldegrun A.S., Klatte T., Shuch B., LaRochelle J.C., Miller D.C., Said J.W., Riggs S.B., Zomorodian N., Kabbinavar F.F., Dekernion J.B., Pantuck A.J. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer 2008, 113:2457-2463.